Daniel Sherbenou, MD, PHD

• Multiple Myeloma

As an undergraduate at the University of Colorado, I started my scientific career focused on basic science research of cancer. In the laboratory of Dr. Min Han, I studied the Ras cell signaling pathway using the C. elegans model organism. In an oncology fellowship at University of California at San Francisco, I focused on the study of antibody-based therapeutics under the mentorship of Dr. Bin Liu. Antibody-drug conjugates (ADCs) are another rapidly growing approach to cancer treatment. With Dr. Liu, I conducted preclinical analyses of a novel ADC for multiple myeloma, that I hope will soon lead to a new clinical treatment option. Now a faculty member at UC Denver in the Hematology division, I oversee a translational research laboratory focused on novel therapy development and optimization for multiple myeloma and will care for patients with myeloma and related plasma cell disorders in Colorado and adjoining areas.